Dashboard
Manage Tickers

SMMT Summit Therapeutics Inc.


$ 21.50 $ 0.00 (0 %)    

Friday, 17-Oct-2025 07:43:57 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 596.54 $ 0.00 (0 %)
DIA $ 459.00 $ 0.00 (0 %)
SPY $ 658.14 $ 0.00 (0 %)
TLT $ 91.26 $ 0.00 (0 %)
GLD $ 395.81 $ 0.00 (0 %)
$ na
$ 23.01
$ 21.50 x 100
$ 22.00 x 267
-- - --
$ 15.55 - $ 36.91
5,783,669
na
16.32B
$ 0.34
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

summit-therapeutics-initiates-global-phase-iii-harmoni-gi3-trial-evaluating-ivonescimab-plus-chemotherapy-in-metastatic-colorectal-cancer
Summit Therapeutics Initiates Global Phase...
10/17/2025 11:04:42

HARMONi-GI3 is the Fourth Global Phase III Study of Ivonescimab and First Global Study beyond NSCLCClinical Trial Site Activati...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

alpha-buying-the-3-stocks-that-just-got-this-1-million-vote-of-confidence
Alpha Buying: The 3 Stocks That Just Got T...
10/01/2025 18:39:50

intel-marvell-electronic-arts-are-among-the-top-10-large-cap-gainers-last-week-sep-22---sep-26-are-the-others-in-your-portfolio
Intel, Marvell, Electronic Arts Are Among ...
09/28/2025 13:25:51

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

summit-therapeutics-harmoni-6-phase-iii-trial-shows-ivonescimab-plus-chemotherapy-significantly-improves-pfs-over-tislelizumab-in-1l-squamous-nsclc-data-to-be-presented-at-esmo-2025-presidential-symposium
Summit Therapeutics' HARMONi-6 Phase III T...
09/24/2025 11:04:48

nvidia-high-fives-palantir-rocket-lab--on-this-list-of-10-bagger-legends
Nvidia High-Fives Palantir, Rocket Lab — O...
09/23/2025 16:40:29

Ten stocks in the large-cap Russell 1000 index have achieved at least 1,000% returns since the October 2022 bull market bottom,...

this-protagonist-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Protagonist Therapeutics Analyst Begi...
09/17/2025 12:15:15

barclays-initiates-coverage-on-summit-therapeutics-with-underweight-rating-announces-price-target-of-13
Barclays Initiates Coverage On Summit Ther...
09/17/2025 11:00:35

Barclays analyst Etzer Darout initiates coverage on Summit Therapeutics (NASDAQ:SMMT) with a Underweight rating and announce...

hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Summ...
09/16/2025 10:53:57

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...

jim-cramer-ring-the-register-on-this-real-estate-meme-stock
Jim Cramer: Ring The Register On This Real...
09/15/2025 12:11:04

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended ditching Opendoor: "We don't want to be in a ...

synopsys-chewy-and-the-trade-desk-are-among-top-10-large-cap-losers-last-week-sep-8--sep-12-are-the-others-in-your-portfolio
Synopsys, Chewy, And The Trade Desk Are Am...
09/14/2025 15:01:21

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biote...

summit-therapeutics-form4-filings-from-late-thursday-show-co-ceos-each-purchased-338394-shares-at-avg-price-of-1769
Summit Therapeutics Form4 Filings From Lat...
09/12/2025 12:17:27

top-3-health-care-stocks-youll-regret-missing-in-q3
Top 3 Health Care Stocks You'll Regret Mis...
09/09/2025 13:12:17

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
09/08/2025 17:07:17

gold-moves-higher-robinhood-shares-jump
Gold Moves Higher; Robinhood Shares Jump
09/08/2025 16:11:19

cantor-fitzgerald-reiterates-overweight-on-summit-therapeuticsto-overweight
Cantor Fitzgerald Reiterates Overweight on...
09/08/2025 13:29:10

Cantor Fitzgerald analyst Eric Schmidt reiterates Summit Therapeutics (NASDAQ:SMMT) from Overweight to Overweight.

summit-therapeutics-lung-cancer-drug-under-dark-clouds-as-keytruda-challenger-shows-regional-data-differences
Summit Therapeutics' Lung Cancer Drug Unde...
09/08/2025 12:28:07

Summit's ivonescimab showed improved survival trends in NSCLC patients with favorable safety, though some results missed st...

new-fortress-energy-posts-q2-loss-joins-summit-therapeutics-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
New Fortress Energy Posts Q2 Loss, Joins S...
09/08/2025 12:10:42

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/08/2025 12:08:53

hc-wainwright--co-reiterates-buy-on-summit-therapeutics-maintains-50-price-target
HC Wainwright & Co. Reiterates Buy on Summ...
09/08/2025 11:52:51

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $50...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION